⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6600790 | 0.88 | — | — | |
| SCHEMBL7869692 | 0.83 | — | — | |
| SCHEMBL7869690 | 0.81 | — | — | |
| SCHEMBL6602461 | 0.81 | — | — | |
| SCHEMBL6600785 | 0.81 | — | — | |
| SCHEMBL6601632 | 0.79 | — | — | |
| SCHEMBL6601458 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL6601474 | 0.78 | — | — | |
| SCHEMBL27413348 | 0.76 | — | — | |
| SCHEMBL6600616 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6136812-A | Methods of administering AMPA receptor antagonists to treat dyskinesias associated with dopamine agonist therapy | PFIZER INC (US) | 2000-10-24 | — | — | US | claimed |
| EP-0900568-A2 | AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy | Pfizer Products Inc. (US) | 1999-03-10 | — | — | EP | claimed |
| US-20200397751-A1 | Modulation of AMPA/kainate Receptors for the Treatment of Hypoglycemia | VANDERKLISH PETER (US) | 2020-12-24 | — | — | US | disclosed |
| WO-2019113110-A2 | MODULATION OF AMPA/KAINATE RECEPTORS FOR THE TREATMENT OF HYPOGLYCEMIA | VANDERKLISH PETER (US) | 2019-06-13 | — | — | WO | disclosed |
| EP-0901487-B9 | 2,3,6 TRISUBSTITUTED-4(3H)-QUINAZOLINONES | PFIZER (US) | 2004-09-29 | — | — | EP | disclosed |
| EP-0968194-B1 | ATROPISOMERS OF 3-ARYL-4(3H)-QUINAZOLINONES AND THEIR USE AS AMPA-RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2004-05-26 | — | — | EP | disclosed |
| EP-0901487-B1 | 2,3,6 TRISUBSTITUTED-4(3H)-QUINAZOLINONES | PFIZER (US) | 2003-06-04 | — | — | EP | disclosed |
| US-6306864-B1 | CEREBRAL DEFICITS SUBSEQUENT TO OR RESULTING FROM CARDIAC BYPASS SURGERY AND GRAFTING, STROKE, CEREBRAL ISCHEMIA, SPINAL CORD TRAUMA, HEAD TRAUMA | PFIZER INC. | 2001-10-23 | — | — | US | disclosed |
| US-6303615-B1 | FOR THERAPY AND PROPHYLAXIS OF NEURODEGENERATIVE DISORDERS, CENTRAL NERVOUS SYSTEM DISORDERS, CONVULSIONS | PFIZER INC | 2001-10-16 | — | — | US | disclosed |
| US-6136812-A | Methods of administering AMPA receptor antagonists to treat dyskinesias associated with dopamine agonist therapy | PFIZER INC (US) | 2000-10-24 | — | — | US | disclosed |
| EP-0968194-A1 | ATROPISOMERS OF 3-ARYL-4(3H)-QUINAZOLINONES AND THEIR USE AS AMPA-RECEPTOR ANTAGONISTS | Pfizer Products Inc. (US) | 2000-01-05 | — | — | EP | disclosed |
| EP-0901487-A1 | NOVEL 2,3 DISUBSTITUTED-4(3H)-QUINAZOLINONES | PFIZER INC. (US) | 1999-03-17 | — | — | EP | disclosed |
| EP-0900568-A2 | AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy | Pfizer Products Inc. (US) | 1999-03-10 | — | — | EP | disclosed |
| WO-1998038173-A1 | ATROPISOMERS OF 3-ARYL-4(3H)-QUINAZOLINONES AND THEIR USE AS AMPA-RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 1998-09-03 | — | — | WO | disclosed |
| WO-1997043276-A1 | NOVEL 2,3 DISUBSTITUTED-4(3H)-QUINAZOLINONES | PFIZER INC. (US) | 1997-11-20 | — | — | WO | disclosed |